Daniel M. Anderson

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3.2K citations · Full text

Medicine, Oncology, Cancer Pharmacology +11

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial

Robert D. McBane, Waldemar E. Wysokiński, Jennifer Le‐Rademacher et al. · Journal of Thrombosis and Haemostasis · 2019 · 578 citations

Medicine, Pharmacology, Pharmacotherapy +14

Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma

Sagar Lonial, Susanna Jacobus, Rafaël Fonseca et al. · Journal of Clinical Oncology · 2019 · 311 citations · Full text

Medicine, Hematology, Pharmacotherapy +15

Comparative Analysis of Hemostatic Agents in a Swine Model of Lethal Groin Injury

Hasan B. Alam, Gemma B. Uy, Dana L. Miller et al. · The Journal of Trauma: Injury, Infection, and Critical Care · 2003 · 165 citations

Medicine, Veterinary Surgery, Hemostasis +16